Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Latarcibart - Incyte Corporation

Next Previous
Drug Profile

Latarcibart - Incyte Corporation

Alternative Names: VGA-039

Latest Information Update: 24 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Star Therapeutics; Vega Therapeutics
  • Developer Incyte Corporation; Star Therapeutics
  • Class Antihaemorrhagics; Coagulants; Monoclonal antibodies
  • Mechanism of Action Protein S inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Von Willebrand disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Von Willebrand disease
  • Phase I/II Blood coagulation disorders

Most Recent Events

  • 13 Jul 2026 Efficacy and adverse events data from a phase I/II trial in Von Willebrand disease released by Incyte Corporation
  • 06 Jul 2026 Vega Therapeutics has been acquired and merged into Incyte Corporation
  • 24 Jun 2026 VGA 039 is still in phase I/II trials for Von Willebrand disease (In adolescents, In the elderly, In adults) in US, Austria, Australia, Brazil, Canada, India, South Africa and United Kingdom (NCT05776069)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top